Its level of expression seemed highest in metastatic states, and therefore, the progressive state of melanoma was directly correlated to the levels of SPHK1 gene, where models with higher levels of SPHK1 expression revealed shorter progression free survival when treated with anti-PD1 therapy [127]. This evidence concerns the gene PDCD1 and melanoma.